July 2023: Phase 2 trial results indicated observed effects relevant to obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD)
Even within the current landscape, some people respond better to one medication over another based on their individual side effect profile
As a physician-led medical spa, we provide safe, medically supervised weight loss treatments tailored to your needs
Elective preprocedural cessation of GLP-1RAs and GLP-1/GIPRAs is not recommended, and risks hyperglycaemia in people with diabetes
Mounjaro is already licensed and has more established safety and longer-term data
As of 2024, retatrutide has not received MHRA or EMA marketing authorisation and is not listed in the BNF